{"id":892287,"date":"2025-10-03T09:33:59","date_gmt":"2025-10-03T13:33:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/"},"modified":"2025-10-03T09:33:59","modified_gmt":"2025-10-03T13:33:59","slug":"akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/","title":{"rendered":"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON and LONDON, Oct.  03, 2025  (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CF8XaVaidjhpLsqJ9j9Uk8CY5uXanTgLBsVqsxwzgStBW-sIhk3KEbQoL8REiUm6IemyJGuHa4yqO6ntvwS7UA==\" rel=\"nofollow\" target=\"_blank\">40<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZitvP71H_V_SzGIntafxTvye62stMX9Zlh917piIEESYfO9InGrU_qsthhAyVJGWO7ov1W4IPOhHInZo0xamtw==\" rel=\"nofollow\" target=\"_blank\"><sup>th<\/sup><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K_LDS98WSqCpnGUkuwL53-sNWvoecnsn2kJAUKBB5n4VMg-5e9AY4NwMvCLSjPwkc5sRm5lzOlMTOhkIPyamOnk-4kLr00sTzpgjVSz-lwYncQxWhcwpvp0pldkuMLXQ\" rel=\"nofollow\" target=\"_blank\"> Annual SITC Meeting<\/a> being held November 5-9, 2025 in National Harbor, MD.<\/p>\n<p align=\"justify\">Details of the oral presentation are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Title:<\/strong><br \/>\n        <em>A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity<\/em><br \/>\n        <br \/>\n        <strong>Presenter: <\/strong>Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari Therapeutics<br \/><strong>Abstract No:<\/strong> 951<br \/><strong>Session:<\/strong> 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune Modulation<br \/><strong>Date and Time:<\/strong> Sunday, November 9, 2025 at 11:05 AM ET<br \/><strong>Location:<\/strong> Gaylord National Resort and Convention Center \u2013 Ballroom Level \u2013 Potomac Ballroom<\/p>\n<p align=\"justify\">\n        <strong>Poster Presentation:<\/strong> Friday, November 7, 2025<br \/><strong>Location:<\/strong> Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center<\/p>\n<p align=\"justify\">For more information about the SITC Annual Meeting, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kf7PUc7GSBckfTztiGpcabxd7J8V7ghyVQNZx8IUcEmsML-wphbjDcy97BAqko2E4pNBioDrgx1NYJj3toU4XTpMQQZADmm5POtl9aPcJHI=\" rel=\"nofollow\" target=\"_blank\">sitcancer.org<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Akari Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Akari\u2019s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.<\/p>\n<p align=\"justify\">For more information about the Company, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-JNdlXYTb0k0_6fpLtJS7KW7StZkBXAL4_DkIMAayiagX5n2GHMhbEDEg9T2Bna9ZBS172-MIHCVNNdFdHEa2LNza-IQII1X3faek8wIrXc=\" rel=\"nofollow\" target=\"_blank\">www.akaritx.com<\/a> and connect on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TuOeLo23oQj-wkebRr0kTyGt6SyFBirqOfNHV9nCVj93ZRDwqigVw-aeaWgYYvpfKz2wPBZXEF_ySNmbaT9LEQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F183iaoFs2suUW5E4TaflTdMU_mPWLZW_7VRstZIxhxaCBDavLz6k1ty2jltAvztm3W9DjnM0RiJkq78Z0tTfOUJYAic6jRzV2FW7sUjKuE=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Cautionary Note Regarding Forward-Looking Statements\u00a0<\/strong><\/p>\n<p>This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that\u00a0involve\u00a0risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cfuture,\u201d \u201copportunity\u201d \u201cwill likely result,\u201d \u201ctarget,\u201d variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other\u00a0diseases, and\u00a0ultimately bring therapies to patients. These statements are based on the Company\u2019s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific.\u00a0A number of\u00a0important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the Company\u2019s need for additional capital; the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and\/or development of the Company\u2019s programs or product candidates; risks related to any loss of the Company\u2019s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company\u2019s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and\/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and\/or its collaborators or licensees may be replicated in other studies and\/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company\u2019s product candidates; risks related to competition for the Company\u2019s product candidates; and the Company\u2019s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should\u00a0be considered to be\u00a0a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the SEC, copies of which may be obtained from the SEC\u2019s website at www.sec.gov. The Company assumes no, and hereby disclaims\u00a0any, obligation to update the forward-looking statements contained in this press release except as required by law.<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact <\/strong>\n      <\/p>\n<p align=\"justify\">JTC Team, LLC <br \/>Jenene Thomas <br \/>908-824-0775 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=efeHQZWHZ3UyJVmYjXbgdNI5eaG8TeUlGzYiJI2BmAPxI5unKeHgP3uWYKoBwRrjGymZQJ0CyrZbrDWjpeTvIw==\" rel=\"nofollow\" target=\"_blank\">AKTX@jtcir.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTFkMzQ0YzYtNzBjZS00NmEyLWI4NjEtNWRiYTc5MmM0NzUzLTEwMzE4MzUtMjAyNS0xMC0wMy1lbg==\/tiny\/Akari-Therapeutics-Plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD. Details of the oral presentation are as follows: Title: A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity Presenter: Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari TherapeuticsAbstract No: 951Session: 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune ModulationDate and Time: Sunday, November 9, 2025 at 11:05 AM ETLocation: Gaylord National Resort and Convention Center \u2013 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-892287","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD. Details of the oral presentation are as follows: Title: A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity Presenter: Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari TherapeuticsAbstract No: 951Session: 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune ModulationDate and Time: Sunday, November 9, 2025 at 11:05 AM ETLocation: Gaylord National Resort and Convention Center \u2013 &hellip; Continue reading &quot;Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-03T13:33:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting\",\"datePublished\":\"2025-10-03T13:33:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/\"},\"wordCount\":958,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/\",\"name\":\"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=\",\"datePublished\":\"2025-10-03T13:33:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Market Newsdesk","og_description":"BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) &#8212; Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral presentation at the 40th Annual SITC Meeting being held November 5-9, 2025 in National Harbor, MD. Details of the oral presentation are as follows: Title: A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity Presenter: Satyajit Mitra Ph.D., Executive Director, Head of Oncology at Akari TherapeuticsAbstract No: 951Session: 302 Beyond Cytotoxic Chemotherapy: the Next Generation of ADCs for Immune ModulationDate and Time: Sunday, November 9, 2025 at 11:05 AM ETLocation: Gaylord National Resort and Convention Center \u2013 &hellip; Continue reading \"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-03T13:33:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting","datePublished":"2025-10-03T13:33:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/"},"wordCount":958,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/","name":"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=","datePublished":"2025-10-03T13:33:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzOTcwNyM3MTc3NzMyIzIwMjAyNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akari-therapeutics-announces-abstract-accepted-for-oral-presentation-at-the-40th-annual-society-for-immunotherapy-of-cancer-sitc-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=892287"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/892287\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=892287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=892287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=892287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}